|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The Effect of Clot Volume and Permeability on Response to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
|
31810719 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The only way of managing patients with ischemic stroke is the use of intravenous tissue plasminogen activator and endovascular thrombectomy.
|
31612315 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Intravenous recombinant tissue plasminogen activator is considered for acute ischemic stroke.
|
31623507 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
|
31478148 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke.
|
31562039 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
In contrast to our hypothesis, younger patients with acute ischemic stroke were more likely to be treated with tPA than older patients, but they were more likely to experience delay in evaluation and treatment.
|
31092622 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
While there is a great debate on proposed mechanisms, fundamental questions regarding resistance to tPA in metabolic syndrome patients with ischemic stroke remain unanswered.
|
30465701 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA).
|
31293500 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Canonical Wnt Pathway Maintains Blood-Brain Barrier Integrity upon Ischemic Stroke and Its Activation Ameliorates Tissue Plasminogen Activator Therapy.
|
30852795 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke.
|
30775405 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The only Food and Drug Administration-approved treatment for acute ischemic stroke is tissue plasminogen activator, and the discovery of novel therapeutic targets is critical.
|
31026065 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
rt-PA: recombinant tissue plasminogen activator; AIS: acute ischemic stroke; sICH: symptomatic intracranial haemorrhage.
|
30822264 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Intravenous thrombolysis with the tissue plasminogen activator (tPA) is the gold standard for acute ischemic stroke.
|
30367009 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke.
|
31293509 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Multiple trials have investigated superiority of tenecteplase compared to tPA for treatment of acute ischemic stroke.
|
30471930 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Tissue plasminogen activator (t-PA) is an effective therapy for acute ischemic stroke, but some patients still have poor clinical outcome.
|
30859753 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Intravenous thrombolysis with recombinant tissue plasminogen activator and endovascular mechanical thrombectomy are known to be the most effective treatments in the acute phase of ischemic stroke.
|
30268366 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Delayed thrombolytic therapy with recombinant tissue plasminogen activator (tPA) may exacerbate blood-brain barrier (BBB) breakdown after ischemic stroke and lead to catastrophic hemorrhagic transformation (HT).
|
31756041 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Intravenous Tissue Plasminogen Activator for Large Vessel Ischemic Stroke - Is There Still a Role?
|
31197340 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The advent of mechanical thrombectomy (MT) has become an effective option for the treatment of acute ischemic stroke in addition to tissue plasminogen activator (tPA).
|
31518981 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Stroke is one of the leading causes of death and disability globally, while intravenous thrombolysis with recombinant tissue plasminogen activator remains the only Food and Drug Administration (FDA)-approved therapy for ischemic stroke.
|
30404981 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Despite being the leading cause of human cerebral damage, there is currently no medical therapy for haemorrhagic stroke and thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for ischaemic stroke.
|
31004788 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
This study provides Class IV evidence that for patients with acute ischemic stroke and NIHSS ≤5 screened with MRI, IV tissue plasminogen activator is safe.
|
31519779 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
|
31235258 |
2019 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Although the efficacy of tissue plasminogen activator (tPA) for acute ischemic stroke is well established, rates of tPA use remain low.
|
31053101 |
2019 |